This article is more than 5 years old. Information may no longer be current.
Cancer institute leader elected to ASCO board of directors
Walter J. Curran, Jr., MD, executive director of the Winship Cancer Institute of Emory University, has been elected to ASCO’s board of directors.
He will be one of four new members whose terms will start in June 2014.
Curran, who specializes in the management of patients with locally advanced lung and brain malignancies, is the only radiation oncologist to serve as director of an NCI-designated cancer center.
“It is truly an honor to be elected to serve on the ASCO board,” Curran said. “I look forward to being a part of the national discussion on how cancer care must evolve over the next decade and how physician-investigators must design and complete the very best clinical trials to further advance the care of our patients.”
Curran is the Lawrence W. Davis professor and chair of Emory’s department of radiation oncology. Since 1997, he has served as group chair and principal investigator of the Radiation Therapy Oncology Group, an NCI-funded cooperative group.
He is one of three founding principal investigators of NRG Oncology, a new NCI-funded research group. He also is chair of the NRG Oncology Foundation board.
“This is the first time an Emory University physician or any Georgia-based doctor has been elected to a seat on the ASCO board,” Wright Caughman, MD, Emory executive vice president for health affairs, CEO of the Woodruff Health Sciences Center and chairman of Emory Healthcare said in a press release. “As the leader of Emory’s Winship Cancer Institute, Wally Curran will make a tremendous contribution to ASCO’s work over the next few years.”
Earlier this year, Curran was named a Georgia Research Alliance eminent scholar and chair in cancer research. He has led several landmark clinical and translational trials for patients with either lung cancer or brain tumors and is responsible for defining a universally adopted staging system for patients with malignant glioma.